[go: up one dir, main page]

WO2008105174A1 - 細胞性免疫誘導用リポソーム - Google Patents

細胞性免疫誘導用リポソーム Download PDF

Info

Publication number
WO2008105174A1
WO2008105174A1 PCT/JP2008/000351 JP2008000351W WO2008105174A1 WO 2008105174 A1 WO2008105174 A1 WO 2008105174A1 JP 2008000351 W JP2008000351 W JP 2008000351W WO 2008105174 A1 WO2008105174 A1 WO 2008105174A1
Authority
WO
WIPO (PCT)
Prior art keywords
liposome
cell
mediated immunity
induction
induce
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/000351
Other languages
English (en)
French (fr)
Inventor
Hideyoshi Harashima
Kentaro Kogure
Takashi Nakamura
Rumiko Moriguchi
Kohei Ono
Homhuan Atthachai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hokkaido University NUC
Original Assignee
Hokkaido University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hokkaido University NUC filed Critical Hokkaido University NUC
Priority to US12/449,670 priority Critical patent/US20100136099A1/en
Priority to EP08720265A priority patent/EP2127670A4/en
Priority to JP2009501134A priority patent/JPWO2008105174A1/ja
Priority to CA002686840A priority patent/CA2686840A1/en
Publication of WO2008105174A1 publication Critical patent/WO2008105174A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

　抗原性物質を封入した、連続した複数個のアルギニン残基を含むペプチドを表面に有するリポソーム。本発明のリポソームは、抗原提示細胞に対してＭＨＣクラスＩ分子を介した抗原提示を選択的に行わせることが出来、細胞性免疫を特異的に誘導することができる。また本発明のリポソームは、成熟化した樹状細胞に対しても抗原提示を誘起することができる。
PCT/JP2008/000351 2007-02-28 2008-02-26 細胞性免疫誘導用リポソーム Ceased WO2008105174A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US12/449,670 US20100136099A1 (en) 2007-02-28 2008-02-26 Liposome for induction of cell-mediated immunity
EP08720265A EP2127670A4 (en) 2007-02-28 2008-02-26 LIPOSOM FOR THE INTRODUCTION OF CELL-MEDIATED IMMUNITY
JP2009501134A JPWO2008105174A1 (ja) 2007-02-28 2008-02-26 細胞性免疫誘導用リポソーム
CA002686840A CA2686840A1 (en) 2007-02-28 2008-02-26 Liposome for induction of cell-mediated immunity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007085627 2007-02-28
JP2007-085627 2007-02-28

Publications (1)

Publication Number Publication Date
WO2008105174A1 true WO2008105174A1 (ja) 2008-09-04

Family

ID=39721016

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/000351 Ceased WO2008105174A1 (ja) 2007-02-28 2008-02-26 細胞性免疫誘導用リポソーム

Country Status (5)

Country Link
US (1) US20100136099A1 (ja)
EP (1) EP2127670A4 (ja)
JP (1) JPWO2008105174A1 (ja)
CA (1) CA2686840A1 (ja)
WO (1) WO2008105174A1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017538754A (ja) * 2014-12-17 2017-12-28 エスアールアイ インターナショナルＳＲＩ Ｉｎｔｅｒｎａｔｉｏｎａｌ 抗原送達系
WO2023095874A1 (ja) * 2021-11-25 2023-06-01 国立大学法人長崎大学 脂質性化合物、リポソーム、エクソソーム、脂質ナノ粒子及びドラッグデリバリーシステム

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992004887A1 (fr) 1990-09-25 1992-04-02 Kyowa Hakko Kogyo Co., Ltd. Production de lymphocites t cytotoxiques
WO2005032593A1 (ja) 2003-10-01 2005-04-14 Japan Science And Technology Agency 核移行能を有するポリアルギニン修飾リポソーム

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1320923C (zh) * 2001-06-29 2007-06-13 中外制药株式会社 含有基于癌抑制基因wt1的产物的癌抗原和阳离子脂质体的癌疫苗

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992004887A1 (fr) 1990-09-25 1992-04-02 Kyowa Hakko Kogyo Co., Ltd. Production de lymphocites t cytotoxiques
WO2005032593A1 (ja) 2003-10-01 2005-04-14 Japan Science And Technology Agency 核移行能を有するポリアルギニン修飾リポソーム

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
MITSUI H. ET AL.: "Polyarginine-mediated protein delivery to dendritic cells presents antigen more efficiently onto MHC class I and Class II and elicits superior antitumor immunity", J. INVEST. DERMATOL., vol. 126, 2006, pages 1804 - 1812, XP008117410 *
NAKAMURA K. ET AL.: "R8 Shushoku Liposome o Mochiita MHC Class I eno Tokuiteki Kogen Teiji", DRUG DELIV. SYST., vol. 22, no. 3, 2007, pages 344, XP001539199 *
NAKAMURA T. ET AL.: "Delivery of condensed DNA by liposomal non-viral gene delivery system into nucleus of dendritic cells", BIOL. PHARM. BULL., vol. 29, no. 6, 2006, pages 1290 - 1293, XP008117412 *
NIKI S.: "Saibo Sentakuteki Targeting o Mezashita Shinki Carrier Peptide no Kaihatsu", RESEARCH PAPERS OF THE SUZUKEN MEMORIAL FOUNDATION, 2003, pages 190 - 194, XP008142259 *
ONO K. ET AL.: "Octa-arginine Shushoku Liposome ni yoru MHC Class I Tokuiteki Kogen Delivery Mechanism no Kaiseki", THE 22ND APSTJ ANNUAL MEETING KOEN YOSHISHU, 2007, pages 293, XP008142258 *
PIETERSZ G.A. ET AL.: "Generation of cellular immune responses to antigenic tumor peptides", CELL. MOL. LIFE. SCI., vol. 57, 2000, pages 290 - 310, XP001083904 *
ROSENBERG ET AL., NAT. MED., vol. 4, 1998, pages 321 - 327
See also references of EP2127670A4
SHASTRI N., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 6020 - 6024
TANEICHI M. ET AL.: "Liposome Hyomen ni Kagaku Ketsugo sareta Kogen wa CD8 Yosei T Saibo ni cross-preent sareta Shuyo Men'eki", DAI 36 KAI JAPANESE SOCIETY FOR IMMUNOLOGY SOKAI . GAKUJUTSU SHUKAI YOKOSHU, 2006, pages 90 + ABSTR. NO. 1-H-W12-11-P, XP008117470 *
ZHANG C. ET AL.: "siRNA-containing liposomes modified with polyarginine effictively silence the targeted gene", J. CONTROLL RELEASE, vol. 112, 2006, pages 229 - 239, XP005410513 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017538754A (ja) * 2014-12-17 2017-12-28 エスアールアイ インターナショナルＳＲＩ Ｉｎｔｅｒｎａｔｉｏｎａｌ 抗原送達系
US10925960B2 (en) 2014-12-17 2021-02-23 Sri International Antigen delivery system
WO2023095874A1 (ja) * 2021-11-25 2023-06-01 国立大学法人長崎大学 脂質性化合物、リポソーム、エクソソーム、脂質ナノ粒子及びドラッグデリバリーシステム

Also Published As

Publication number Publication date
US20100136099A1 (en) 2010-06-03
CA2686840A1 (en) 2008-09-04
EP2127670A1 (en) 2009-12-02
JPWO2008105174A1 (ja) 2010-06-03
EP2127670A4 (en) 2010-03-24

Similar Documents

Publication Publication Date Title
USD671494S1 (en) Motor starter display
MX2010008799A (es) Proceso para estabilizar una composicion de vacuna que contiene adyuvante.
WO2012177924A3 (en) Influenza virus mutants and uses therefor
WO2005002621A3 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
WO2012051211A3 (en) Antigen delivery platforms
GB2439474B (en) LI-Key/Antigenic epitope hybrid peptide vaccines
WO2012006367A3 (en) Compositions and methods for treating influenza
WO2011109833A3 (en) Induced dendritic cell compositions and uses thereof
WO2009022154A3 (en) Peptide with multiple epitopes
WO2011106607A3 (en) Subunit vaccines for herpes viruses and methods of use
MX2010001284A (es) Vacunas contra la influenza con multiepitope multimerico.
EP3213765A3 (en) Antigen-specific t cell receptors and t cell epitopes
ZA200905347B (en) Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells
WO2011091376A3 (en) Immunogenic influenza composition
AR080585A1 (es) Vacunacion contra tumores que comprende una respuesta inmune humoral contra proteinas propias
MY143347A (en) Mucosal immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
WO2012027717A3 (en) Flourescence labeling reagents and uses thereof
WO2011153400A3 (en) Nasal immunization
NZ630133A (en) Vaccines for serogroup x meningococcus
SG158154A1 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
WO2008105174A1 (ja) 細胞性免疫誘導用リポソーム
WO2009143105A3 (en) Method and apparatus for providing a synchronous interface for an asynchronous service
WO2007052057A3 (en) Adminstration routes for priming/boosting with influenza vaccines
WO2007082734A3 (en) Influenza vaccine
WO2005120564A3 (en) Vaccine compositions and methods

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08720265

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009501134

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008720265

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2686840

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12449670

Country of ref document: US